



Commercial/Healthcare Exchange Quantity Limit Criteria
Effective: July 8, 2020

Quantity Limit Name: Pemazyre

Products Affected: Pemazyre (pemigatinib) oral tablets

Type of Quantity Limit:

- FDA maximum
- Usual Daily Frequency
- Split fill
- Other (Please specify): _____

Limits to be applied:

Pemazyre 4.5mg tablets	Quantity Limit: 14 tablets per 21 days
Pemazyre 9mg tablets	Quantity Limit: 14 tablets per 21 days
Pemazyre 13.5mg tablets	Quantity Limit: 14 tablets per 21 days

References:

1. Pemazyre (pemigatinib) [prescribing information]. Wilmington, DE: Incyte Corporation; April 2020.

Policy Revision history

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	6/30/2020

Last Res. June 2020



Confidential Information

This document is confidential and proprietary to ConnectiCare. Unauthorized use and distribution are prohibited.